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Radioimmunoconjugates are promising agents in diagnostics and treatment of different 
types of cancers. The aim of this study was the formulation of stable freeze dried kits of trastu-
zumab with three types of bifunctional chelators for further radiolabeling. The integrity of the 
antibody in formulated conjugates was examinated with sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). 
Trastuzumab is a humanized monoclonal antibody used in the therapy of aggressive 
HER2 positive breast cancer. Conjugation of trastuzumab was made with various chelators: p-
SCN-Bn-DTPA (1:10; 1:20; 1:50), p-SCN-Bn-DOTA (1:20), and 1B4M-DTPA (1:10; 1:20; 
1:50). The purified immunoconjugates were lyophilized by applying two day protocol in order to 
produce the stable freeze dried kits. Cold labeling with nonradioactive isotopes LuCl3 and YCl3 
was performed to examine the possible modifications of secondary structure after radioactive 
labeling. SDS-PAGE electrophoresis was used to estimate the purity and integrity of the an-
tibody before and after conjugations, lyophilization and labeling under reducing conditions. 
The obtained results show that there is no degradation of the examined antibody. The 
trastuzumab-conjugates and cold labeled formulations migrated in two bands (∼50 kDa and 
∼25 kDa), in the same way as IgG1 antibodies and unmodified trastuzumab.  
Acta Medica Medianae 2019;58(3):15-23. 
 
Key words: Bifunctional chelators, conjugations, electrophoresis, trastuzumab 
 
 
1University "Goce Delčev", Faculty of Medical Sciences, Štip, RN 
Macedonia 
2University of Niš, Faculty of Medicine, Department of 
Pharmacy, Niš, Serbia 
3University Clinic of Radiotherapy and Oncology, Skopje, RN 
Macedonia 
 
 
Contact: Marija Sterjova 
Sutjeska 43b/5, Štip, RN Macedonia 
E-mail: marija.sterjova@ugd.edu.mk 
 
 
 
 
 
Introduction 
 
The human epidermal growth factor receptor 
(HER2) is overexpressed on a surface of the cells in 
aggressive breast cancer. HER2 positive breast can-
cers without anti-HER2 therapy lead to metastasis 
and very low survival rates of the patients (1). Tras-
tuzumab is the first approved humanized monoclo-
nal antibody. It's a potent anti-HER2 antibody which 
originates from murine 4D5 antibody (2). Carter et 
al., 1992 (3) cloned hypervariable regions from 4D5 
in plasmids which are encoding formation of constant 
regions from human IgG1 antibody. A vector that is 
encoding formation of chimeric antibody, which is 
additionally humanized, was successfully generated. 
Trastuzumab is binding to the IV subdomain of the 
receptor and manifests the effect through antibody-
dependent cellular cytotoxicity (4).  
Conjugated antibodies provide high expecta-
tion for development of cancer-specific cytotoxic re-
agents. Each immunoconjugate has an enhanced 
therapeutic specificity due to the conjugation with an-
tibody which shows specificity to a particular antigen 
on the surface of tumor cells (5). Radioimmunocon-
jugates are step forward in diagnostic and treatment 
of different types of cancers (6). Until now, there is 
no FDA registration of trastuzumab-radioimmunocon-
jugates for commercial use. A series of clinical and 
preclinical trials of radioimmunoconjugates for treat-
ment and imaging of breast cancer with different 
radionuclides 111In (7-9), 99mTc (10), 67Ga (11), 90Y, 
86Y (12), 177Lu (13, 14) have been made in the past 
few years. Creation of stable immunocon-jugate with 
bifunctional chelators (BFCAs) is required in order to 
obtain succsessful labeling. This chelator allows 
binding to the antibody on the one side and 
coordinative binding of radioisotopes on the opposi-
te. The commonly investigated chelators are: DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace-
tic acid), DTPA (diethylene triamine pentaacetic acid), 
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DTPA derivate 1B4M-DTPA (2-(4-isothi-ocyanatoben-
zyl)-6-methyl-diethylene-triaminepenta-acetic acid) 
and EDTA (ethylenediamine tetraacetic acid) (15). 
Due to the easy chemical and physical degradations, 
monoclonal antibodies are not stable in water solu-
tions. The commonly processes of preparations are 
denaturation, deamidation, oxidation, deglycolisation, 
aggregation, precipitation and adsorption. In order to 
prolong the life of protein pharmaceuticals, it is ne-
cessary to remove the water from the product. The 
commonly used method is lyophilization which ob-
tains stable freeze dried kits (16).  
Examinations with non-radioactive isotopes (Lu 
and Y) are done with intention to confirm that there 
are no changes in the secondary structure of the 
antibody after coordinative binding of the metal, be-
cause these studies are impossible with radioactive 
isotopes (17). Reducing sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) is impor-
tant for the determination of molecular mass (Mr) as 
well as the possible degradations of trastuzumab, tra-
stuzumab-immunoconjugates and cold labeled kits 
too (18).  
The aim of this study was formulation of sta-
ble freeze dried kit of trastuzumab with p-SCN-Bn-
DOTA (2-(4-izothiocyanatobenzyl)-1,4,7,10-tetraaza-
cyclododecane-1,4,7,10-tetraacetic acid), p-SCN-Bn-
1B4M-DTPA (2-(4-isothiocyanatobenzyl)-6-methyldi-
ethylene-triaminepentaacetic acid) and p-SCN-Bn-
DTPA (2-(4-izothiocyanatobenzyl)-diethylenetriami-
nepentaacetic acid) and subsequently labeling with 
cold isotopes (Lu and Y). Protein integrity determi-
nation and possible aggregations were investigated 
by using reducing one-dimensional SDS-PAGE. 
 
Material and methods 
 
Purification of trastuzumab. Trastuzumab was 
purified from Herceptin® (Hoffmann-La Roche, Basel, 
Switzerland) with Amicon® Ultra-4 (Sigma Aldrich, 
Missouri, USA), 30 KDa for ultrafiltration for 1 hour 
at 5000 rpm, by washing the antibody in six cycles 
with 0.1 M PBS, pH = 8, using HuMax 4k (Human, 
Wiesbaden, Germany) centrifuge.  
Conjugation of trastuzumab. The conjugations 
were made by mixing the antibody with 10 mg/mL 
solution of BFCAs in different molar ratio (p-SCN-Bn-
DTPA – 1:10; 1:20; 1:50, 1B4M-DTPA – 1:10; 1:20; 
1:50 and p-SCN-Bn-DOTA – 1:20) and 18 hours 
incubation on 4 °C with gentle shaking. The immu-
noconjugates were purified with six cycles of ultra-
filtration (Amicon® Ultra-4, 30 KDa), by rinsing with 
0.05 M ammonium acetate, pH = 7. The concen-
tration was adjusted to 1 mg/mL using the 6715 
UV/Vis Spectrophotometer Jenway® (Stafford-shire, 
UK). 
Lyophilization of trastuzumab-immunoconjugates. 
The volume of 1 mL of the solution was transferred 
to type I glass vials and lyophilized to solid state. 
The immunoconjugates were lyophilized with cryo-
protectant and bulking agent, 1% mannitol (50 µL in 
each vial). The lyophilization was performed with 
Labconco Free Zone Stoppering Tray Dryer (Kansas 
City, Missouri, USA), using the protocol by Gjorgieva 
Ackova et al., 2014 (19), with several modifications. 
The samples were equally placed on the shelves 
after reaching the temperature of 4 °C. The first step 
was freezing the samples. The temperature was 
decreased at -40 °C, 1 °C/min (rate of cooling, from 
4 °C to -40 °C) and the time of keeping was 5 hours. 
The second phase of preparation was primary drying 
at the temperature of -10 °C, 0.15 °C/min (rate of 
heating, from -40 °C to -25 °C) for 28 hours and 
pressure of 0.133 mBar. The third part was second-
ary drying on 25 °C, 0.2 °C/min (rate of heating, 
from -25 °C to 25 °C) for 14 hours. The whole 
protocol of lyophilization is shown in Figure 1. After 
completing freeze drying, the vials were closed and 
kept at 4 °C in order to perform the following exam-
inations. 
 
 
 
 
 
 
Figure 1. Lyophilization protocol 
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Labeling trastuzumab-immunoconjugates with 
non-radioactive Lu and Y 
 
The solutions of non-radioactive Lu and Y were 
prepared by dissolving of LuCl3 to concentration of 
1.0709 µg/µL (equivalent to maximum tolerated dose 
(MTD) of 177Lu (4377,1 MBq)) and YCl3 to concen-
tration of 1.1555 mg/µL (equivalent to MTD of 90Y 
(1049,69 MBq)). The immunoconjugates were dis-
solved with sterile 0.9% solution of NaCl and then 
labeled with 1 µL of prepared solution of cold Lu and 
Y to total volume of 1 mL. The labeled DTPA and 
1B4M-DTPA conjugates were incu-bated for 30 min 
at 25 ºC as well as DOTA conjugates were incubated 
for 1 hour at 40 ºC. 
 
Integrity examinations with sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Gel electrophoresis was performed under re-
ducing conditions with Enduro® Modular Vertical Gel 
Electrophoresis System (Labnet, Edison, NJ, USA), 
using mercaptoethanol. In this process, 12% sepa-
rating acrylamide/bisacrylamide gel and 4% stacking 
gel was prepared according to the protocol of the 
manufacturer manual instructions. Electrophoresis 
was performed three times, under the same condi-
tions. Concentration of each sample was 1 mg/mL. 
At the first gel, unmodified trastuzumab and freeze 
dried immunoconjugates were applied after recon-
stitution with 0.9% NaCl. At the second and the third 
gel, immunoconjugates were applied labeled with 
non-radioactive Lu and Y. A mass of 30 µg of sample 
was added in 10 µL of loading buffer. Then the mix-
tures were heated for 5 min at dry bath at 98.5 ºC 
and centrifuged for 5 min at 5000 rpm. 25 µL of 
each sample and 10 µL of SigmaMarkerTM, Wide 
Range, Molecular Weight (Saint Louis, MO, USA) 
were applied in wells of stacking gel. According to 
our previous studies, constant voltage at 150 V and 
approximately current at 23 mA has been used as 
optimum condition. After finishing the entire process 
(which lasted approximately an hour and a half), the 
gel was placed for Coomassie staining for 20 hours. 
Discoloration was observed in the solution composed 
of water, methanol and acetic acid for 7-8 hours. All 
used reagents were from Sigma-Aldrich (Missouri, 
USA). The prepared gels were scanned with Glite 
900 BW Gel Scanner (PacificImage, Torrance, CA). 
 
Results 
 
Stable freeze dried kits of trastuzumab-im-
munoconjugates were formulated. The structures of 
used BFCAs are shown in Figure 2. There are various 
groups (anhydride, bromoacetamid, isothiocyanate) 
that can be attached to the BFCAs molecules, to 
achieve an easier conjugation (17). The chelators 
have 4-izothiocyanatobenzyl groups in theirs struc-
tures which participate in the process of binding to 
the antibody (Figure 3). Thiourea linkage is created 
due to reaction between amino groups of lysine res-
idues of trastuzumab and isothiocyanate groups of 
chelators (20). To remove the water and increase 
the stability, the immunoconjugates were lyophilized 
using the previously described protocol. The whole 
process included freezing of the sample and then 
removing the water by sublimation in a vacuum en-
vironment. After performing the freeze drying pro-
cess solid formulations with a homogeneous struc-
ture were obtained. For further examinations, the 
stable freeze dried cakes were used. The integrity of 
the protein, purity and possible formation of aggre-
gates after lyophilization and after cold labeling were 
established with SDS-PAGE. For comparison, unmod-
ified trastuzumab in a concentration of 1 mg/mL was 
used. The electrophoresis was performed under re-
ducing conditions. Disulfide bonds were reduced with 
2-mercaptoethanol and antibody was separated in 
two fragments: two heavy chains ∼50 kDa and two 
light chains ∼25 kDa (Figure 4) (21). The gel with 
unmodified trastuzumab and trastuzumab-immuno-
conjugates with different molar ratio of BFCAs is 
shown in Figure 5. The gels with cold labeled im-
munoconjugates are shown in Figure 6 and Figure 7, 
as well. 
 
 
 
 
 
 
 
Figure 2. Structure of BFCAs 
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Figure 3. Reaction of conjugation 
 
 
 
 
 
 
Figure 4. Reducing SDS-PAGE 
 
 
 
 
 
 
 
Figure 5. Reducing SDS-PAGE of Trastuzumab 1 mg/mL (1); 
DTPA-Trastuzumab (1:10) (2); DTPA-Trastuzumab (1:20) (3); 
DTPA-Trastuzumab (1:50) (4); 
DOTA-Trastuzumab (1:20) (5); 
1B4M-DTPA-Trastuzumab (1:10) (6); 
1B4M-DTPA-Trastuzumab (1:20) (7); 
1B4M-DTPA-Trastuzumab (1:50) (8). 
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Figure 6. Reducing SDS-PAGE of Y-DTPA-Trastuzumab (1:10) (1);  
Lu-DTPA-Trastuzumab (1:10) (2);  
Y-DTPA-Trastuzumab (1:20) (3);  
Lu-DTPA-Trastuzumab (1:20) (4);  
Y-DTPA-Trastuzumab (1:50) (5);  
Y-DTPA-Trastuzumab (1:50) (6);  
Y-DOTA-Trastuzumab (1:20) (7);  
Lu-DOTA-Trastuzumab (1:20) (8). 
 
 
 
 
Figure 7. Reducing SDS-PAGE of Y-1B4M-DTPA-Trastuzumab (1:10) (1);  
Lu-1B4M-DTPA-Trastuzumab (1:10) (2);  
Y-1B4M-DTPA-Trastuzumab (1:20) (3); 
Lu-1B4M-DTPA-Trastuzumab (1:20) (4);  
Y-1B4M-DTPA-Trastuzumab (1:50) (5);  
Lu-1B4M-DTPA-Trastuzumab (1:50) (6). 
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Discussion 
 
Lyophilization has a major significance in the 
process of formulation of stable pharmaceutical prod-
ucts (vaccines, monoclonal antibodies and protein 
formulation). Properly selected conditions are essen-
tial for complete removal of water and retention of 
the structural integrity of the proteins. They are nec-
essary procedures for obtaining stable, homoge-
neous cakes with flat surfaces which retain the pro-
perties after reconstitution. The first step, freezing, is 
important to the process of separation of the water 
from the solution and leads the protein to crystalline 
state, which is more stable. Control of crystallization 
and size of crystals during the freezing are critical 
parameters and the appropriate selection of cooling 
rate is very important. It is already known that slow 
cooling provides larger crystals, while faster freezing 
provides smaller crystals. On the other side, the fast-
er cooling can lead to aggregations and denaturation 
of the antibody. During preparation of aqueous for-
mulations, it is necessary to place them on the 
cooled shelves to 4-5 ºC (22). With an intention to 
improve the crystallization, the annealing step is of-
ten included (23). Our research team has already 
some experience with freeze drying of monoclonal 
antibody rituximab. Namely, Gjorgieva Ackova et al., 
2014 (19) used a three day protocol with included 
annealing process. The obtained results were prom-
ising, since stable cakes with no aggregates and de-
naturation of the antibody were produced. But, our 
goal was to shorten the length of procedures in two 
days with exclusion of the annealing step. Also, we 
tried to show that with the application of cooling rate 
of 1 º C/min we could obtain cakes with the same 
quality. The choice of the mentioned cooling rate 
was done based on results of the study of Tang and 
Pikal, 2004 (24). Our improvement of procedure of a 
super cooling without phase of separation and a 
uniform of ice structure was reached with the same 
rate of freezing. 
The primary drying is the second step of ly-
ophilization when the majority of frozen bulk water is 
removed by sublimation in a vacuum environment. 
Instead of 25 hours, the time was prolonged to 28 
hours. Also, the secondary drying time was extended 
to 14 hours. At this phase some bound unfrozen 
water is removed at temperatures higher than 25 ºC 
(23). Many sugars (glucose, mannitol or trehalose) 
can be used like cryoprotectants, to protect the pro-
teins from denaturation and inactivation during the 
process of freezing (25). Nounou et al., 2005 (26) 
have shown in their study that obtained freeze dried 
cakes without any cryoprotectant possessed a com-
pact structure but also demonstrated difficulties in 
process of reconstitution. This is probably the result 
of using sugars as bulking agents in production of 
fluffy cakes for easy reconstruction. In our studies to 
protect the antibody from stress temperature and to 
obtain elegant cakes for easy reconstitution 1% 
mannitol was used. After the dissolving of the cakes 
with 0.9% NaCl for less than a minute, clear to opal-
escent solutions were obtained without presence of 
visible solid particles and colloids. 
The processes of conjugation and freeze dry-
ing of the antibodies can lead to changes in protein 
integrity (aggregations and fragmentations). It is im-
portant to show that after cold labeling with Y and 
Lu, the metal does not change the structure of anti-
body. One of the most important methods for exam-
ination of protein integrity and purity is SDS-PAGE in 
reducing conditions (size-based method, where se-
paration is based on the size of the molecules) (17, 
27). Many stability studies of trastuzumab were 
made using a SDS-PAGE in reducing or non-reducing 
conditions. Under reducing conditions, trastuzumab 
was migrated as two bands a ∼50 kDa and ∼25 kDa 
(Mr of heavy and light chain), while under non-redu-
cing conditions only one band at ~150 kDa was ob-
served (Mr of whole antibody) (18, 28, 29). Our 
group has already used the applied method of redu-
cing electrophoresis for integrity examinations of 
rituximab after conjugation and lyophilization (17, 
19).  
Almost the same conditions were used for 
exammination of trastuzumab, with several modifi-
cations. In order to achieve reducing conditions, in-
stead of dithiothreitol, 2-mercaptoethanol was used. 
The SDS -PAGE examinations were performed after 
six months storage of the freeze dried kits at the 
temperature of 4 ºC. The cold labeling was done be-
fore starting the process of electrophoresis. The ob-
tained results of migration of formed samples cor-
respond to already published results for other IgG1 
monoclonal antibodies (18, 28). Under reducing con-
ditions, migration of the trastuzumab provided sepa-
ration of two bands of fragments with molecular 
weight of 25 kDa for light chain and 50 kDa for 
heavy chain, proven with the Wide Range, molecular 
weight marker. The same intensity of the fragments 
of lyophilized and labeled conjugates with the frag-
ments of pure commercial (unmodified) trastuzumab 
indicated that there was no degradation of the an-
tibody. The results have shown that the conjugation, 
lyophilization and label-ing were successful, without 
any damage to the anti-body, with absence of frag-
mentation, denaturation and aggregation of the tra-
stuzumab. 
 
Conclusion 
 
The results of electrophoretic examination have 
shown that stable freeze dried conjugates of tra-
stuzumab were formulated with BFCAs in different 
molar ratios. The integrity and purity of the antibody 
were retained after cold labeling with Y and Lu. 
Therefore, these kits will be used for further char-
acterization of the secondary structure of the anti-
body and determination of the number of the che-
lators with Infra Infrared Spectroscopy (IR), Raman 
Spectroscopy and Matrix Assisted Laser Desorption 
Ionization Time of Flight Mass Spectrometer (MALDI-
TOF-MS). Moreover, immunoconjugates are good 
basis for radiolabeling with application of 177Lu and 
90Y and therefore further researches will be done in 
order to evaluate the potential role of these conju-
gates in diagnostics and therapy of metastatic breast 
cancer. 
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Radioimunokonjugati su agensi za koje se smatra da imaju veliki potencijal u dija-
gnostici i lečenju različitih tipova kancera. Cilj ove studije je formulacija stabilnih liofiliziranih 
kitova trastuzumaba korišćenjem tri vrste bifunkcionalnih helatora, radi daljeg radioaktivnog 
obeležavanja. Integritet antitela u formulisanim konjugatima ispitivan je primenom natrijum 
dodecil sulfat poliakrilamid gel elektroforeze (SDS-PAGE). 
Trastuzumab je humanizovano monoklonsko antitelo koje se koristi u terapiji agresi-
vnog HER2 pozitivnog kancera dojke. Konjugacija trastuzumaba izvršena je korišćenjem ra-
zličitih helatora: p-SCN-Bn-DTPA (1:10; 1:20; 1:50), p-SCN-Bn-DOTA (1:20), i 1B4M-DTPA 
(1:10; 1:20; 1:50). Prečišćeni imunokonjugati liofilizirani su primenom dvodnevnog protokola 
kako bi se dobili stabilni liofilizirani kitovi. Hladno obeležavanje neradioaktivnim izotopima 
LuCl3 i YCl3 izvršeno je da bi se uočile potencijalne modifikacije sekundarne strukture nakon 
radioaktivnog obeležavanja. SDS-PAGE elektroforeza u uslovima redukcije korišćena je za ut-
vrđivanje čistoće i integriteta antitela pre i posle konjugacije, liofilizacije i obeležavanja. 
Na osnovu dobijenih rezultata nije uočena degradacija ispitivanog antitela. Trastuzu-
mab-konjugati i hladno obeležene formulacije migriraju u dve trake (∼50 kDa i ∼25 kDa), na 
isti način kao IgG1 antitela i nemodifikovani trastuzumab. 
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